printer friendly page
Upstate Home
SUNY Upstate Medical university Psychiatry
"I've learned more about the
art of psychiatry than I
could ever have imagined".
THE CENTER LIBRARY

The Center Library—Articles

  1. Cornelius, J.R., et al., Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial [see comments]. Archives of General Psychiatry, 1997. 54(8): p. 700-5.
  2. LeMarquand, D., R.O. Pihl, and C. Benkelfat, Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biological Psychiatry, 1994. 36(5): p. 326-37.
  3. Stein, M.B., et al., Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. Journal of Clinical Psychopharmacology, 1996. 16(3): p. 218-22.
  4. Kushner, M.G., K.J. Sher, and D.J. Erickson, Prospective analysis of the relation between DSM-III anxiety disorders and alcohol use disorders. American Journal of Psychiatry, 1999. 156(5): p. 723-32.
  5. Sees, K.L., et al., Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial [see comments]. JAMA, 2000. 283(10): p. 1303-10.
  6. Swartz, M.S., et al., Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Social Psychiatry & Psychiatric Epidemiology, 1998. 33 Suppl 1: p. S75-80.
  7. George, Nicotine Transdermal Patch and Atypical Antipsychotic Medications for Smoking Cessation in Schizophrenia. Am. J. Psychiatry, 2000. 157(11): p. 1835-1842.
  8. Johnson, A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence. The New England Journal of Medicine, 2000: p. 1290-1334.
  9. Kendler, K.S., et al., Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Archives of General Psychiatry, 2000. 57(3): p. 261-9.
  10. Maxwell, Use of Naltrexone in the Treatment of Alcohol Use Disorders in Patients with Concomitant Major Mental Illness. Journal of Addictive Diseases, 2000. 19(3): p. 61-69.
  11. Sofuoglu, Individual Differences in the Subjective Response to Smoked Cocaine in Humans. Am. J. Drug Alcohol Abuse, 2000. 26(4): p. 591-602.
  12. Singha, Sex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans. Am J. Drug Alcohol Abuse, 2000. 26(4): p. 643-657.
  13. Penk, W.E., et al., Characteristics of substance-abusing persons with schizophrenia: the paradox of the dually diagnosed. Journal of Addictive Diseases, 2000. 19(1): p. 23-30.
  14. Dixit, A.R. and R.M. Crum, Prospective study of depression and the risk of heavy alcohol use in women. American Journal of Psychiatry, 2000. 157(5): p. 751-8. , et al., Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases, 2000. 19(1): p. 71-83.
  15. Mendlowicz, M.V. and M.B. Stein, Quality of life in individuals with anxiety disorders. American Journal of Psychiatry, 2000. 157(5): p. 669-82.
  16. Cherpitel, Performance of Screening Instruments for Alcohol Problems in the ER: A Comparison of Mexican-Americans and Mexicans in Mexico. Am J. Drug Alcohol Abuse, 2000. 26(4): p. 683-702.
  17. Chitwood, A Comparison of the Need for Health Care and Use of Health Care by Injection-Drug Users, Other Chronic Drug Users, and Nondrug Users. American Behavioral Scientist, 1998. 41(8): p. 1107-1122.
  18. Dhopesh, Survey of Hepatitis B and C in Addiction Treatment Unit*. Am. J. Drug Alcohol Abuse, 2000. 26(4): p. 703-707.
  19. Peele, Exploring psychological benefits associated with moderate alcohol use: a necessary corrective to assessments of drinking outcomes? Drug & Alcohol Dependence, 2000. 60: p. 221-247.
  20. Strakowski, S.M. and M.P. DelBello, The co-occurrence of bipolar and substance use disorders. Clinical Psychology Review, 2000. 20(2): p. 191-206.
  21. Dixon, L., Screening for Mental Illness With the Addiction Severity Index. The American Journal on Addictions, 1996. 5: p. 301-307.
  22. Blanchard, J.J., et al., Substance use disorders in schizophrenia: review, integration, and a proposed model. Clinical Psychology Review, 2000. 20(2): p. 207-34.
  23. Kosten, T.R., A. Markou, and G.F. Koob, Depression and stimulant dependence: neurobiology and pharmacotherapy. Journal of Nervous & Mental Disease, 1998. 186(12): p. 737-45.
  24. Kessler, R.C., et al., Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry, 1997. 54(4): p. 313-21.
  25. Sarr, Using cluster analysis of alcohol use disorders to investigate 'diagnostic orphans': subjects with alcohol dependence symptoms but no diagnosis. Drug & Alcohol Dependence, 2000. 60: p. 295-302.
  26. Gordis E, F.R., Addiction - Project Match. Addiction, 1999. 94(1): p. 57-59.
  27. Baldwin, D., et al., Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. British Journal of Psychiatry, 1999. 175: p. 120-6.
  28. Schiller, M.J., M. Shumway, and S.L. Batki, Utility of routine drug screening in a psychiatric emergency setting. Psychiatric Services, 2000. 51(4): p. 474-8.
  29. Samoluk, S.B. and S.H. Stewart, Anxiety sensitivity and situation-specific drinking. Journal of Anxiety Disorders, 1998. 12(5): p. 407-19.
  30. Shumway, M., Symptom Heterogeneity in Comorbid Alcohol Disorder. The Journal of Mental Health Administration, 1996. 23(3): p. 338-347.
  31. Trull, T.J., et al., Borderline personality disorder and substance use disorders: a review and integration. Clinical Psychology Review, 2000. 20(2): p. 235-53.
  32. Casarett, D., J.H. Karlawish, and J. Sugarman, Determining when quality improvement initiatives should be considered research: proposed criteria and potential implications. JAMA, 2000. 283(17): p. 2275-80.
  33. Petry, N.M., A comprehensive guide to the application of contingency management procedures in clinical settings. Drug & Alcohol Dependence, 2000. 58(1-2): p. 9-25.
  34. Johnson, Ondansetron for Reduction of Drinking Among Biologically Predisposed Alcoholic Patients. JAMA, 2000. 284(8).
  35. Bellack, A.S. and J.S. Gearon, Substance abuse treatment for people with schizophrenia. Addictive Behaviors, 1998. 23(6): p. 749-66.
  36. Brown, S., Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry, 1997. 171: p. 502-8.
  37. Bijl, R.V. and A. Ravelli, Psychiatric morbidity, service use, and need for care in the general population: results of The Netherlands Mental Health Survey and Incidence Study. American Journal of Public Health, 2000. 90(4): p. 602-7.
  38. Alex, American Psychiatric Press Reference Library 2.0. JAMA, 2000. 284(8).
  39. Drake, R.E. and K.T. Mueser, Psychosocial approaches to dual diagnosis. Schizophrenia Bulletin, 2000. 26(1): p. 105-18.
  40. Dixon, L., S. McNary, and A. Lehman, One-year follow-up of secondary versus primary mental disorder in persons with comorbid substance use disorders. American Journal of Psychiatry, 1997. 154(11): p. 1610-2.
  41. Neufeld, K.J., et al., Incidence of DIS/DSM-IV social phobia in adults. Acta Psychiatrica Scandinavica, 1999. 100(3): p. 186-92.
  42. Cassano, G.B., et al., Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. Journal of Clinical Psychiatry, 1998. 59(2): p. 60-8.
  43. Rosenberg, S.D., et al., Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. American Journal of Psychiatry, 1998. 155(2): p. 232-8.
  44. Weinrieb, R.M. and C.P. O'Brien, Naltrexone in the treatment of alcoholism. Annual Review of Medicine, 1997. 48: p. 477-87.
  45. Liebowitz, M.R., et al., Social phobia or social anxiety disorder: what's in a name? [letter]. Archives of General Psychiatry, 2000. 57(2): p. 191-2.
  46. Chen, H.T., et al., 3H-paroxetine binding in brains of alcoholics. Psychiatry Research, 1991. 38(3): p. 293-9.
  47. Cooper, S.M., et al., The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol. Acta Psychiatrica Scandinavica, Supplementum, 1989. 350: p. 53-5.
  48. Cornelius, J.R., et al., Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacology Bulletin, 1998. 34(1): p. 117-21.
  49. Cami, Human Pharmacology of 3, 4-Methylenedioxymethamphetamine ("Ecstasy"): Psychomotor Performance and Subjective Effects. Journal of Clinical Psychopharmacology, 2000. 20(4): p. 455-466.
  50. de Boer, M.C., G.M. Schippers, and C.P. van der Staak, Alcohol and social anxiety in women and men: pharmacological and expectancy effects. Addictive Behaviors, 1993. 18(2): p. 117-26.
  51. Otto, M.W., et al., Alcohol dependence in panic disorder patients. Journal of Psychiatric Research, 1992. 26(1): p. 29-38.
  52. Bigby, J., H.N. Barnes, and D.E. Girard, Substance abuse: an annotated bibliography. Occupational Medicine, 1989. 4(2): p. 373-86.
  53. Stein, M.B., Phenomenology and epidemiology of social phobia. International Clinical Psychopharmacology, 1997. 12 Suppl 6: p. S23-6.
  54. Mungas, D., C.L. Ehlers, and T.L. Wall, Effects of acute alcohol administration on verbal and spatial learning. Alcohol & Alcoholism, 1994. 29(2): p. 163-9.
  55. Himle, J.A., et al., Effect of alcohol on social phobic anxiety. American Journal of Psychiatry, 1999. 156(8): p. 1237-43.
  56. Schuckit, M.A., et al., The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction, 1997. 92(10): p. 1289-304.
  57. Thomas, D.L., et al., The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA, 2000. 284(4): p. 450-6.
  58. Olfson, M., et al., Barriers to the treatment of social anxiety. American Journal of Psychiatry, 2000. 157(4): p. 521-7.
  59. Lieber, C.S., Alcoholic liver disease: new insights in pathogenesis lead to new treatments. Journal of Hepatology, 2000. 32(1 Suppl): p. 113-28.
  60. Ramsay, M.A., Measuring level of sedation in the intensive care unit [letter]. JAMA, 2000. 284(4): p. 441-2.
  61. Roy-Byrne, P.P., et al., Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 2000. 20(2): p. 129-36.
  62. Hindmarch, I., A review of the psychomotor effects of paroxetine. International Clinical Psychopharmacology, 1992. 6 Suppl 4: p. 65-7.
  63. Vermeulen, T., Distribution of paroxetine in three postmortem cases [see comments]. Journal of Analytical Toxicology, 1998. 22(6): p. 541-4.
  64. Mueser, K.T., R.E. Drake, and K.M. Miles, The course and treatment of substance use disorder in persons with severe mental illness. NIDA Research Monograph, 1997. 172: p. 86-109.
  65. Antony, M.M., Assessment and treatment of social phobia. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie, 1997. 42(8): p. 826-34.
  66. Bigby, J., H.N. Barnes, and D.E. Girard, An annotated bibliography for general internists. Substance abuse. Journal of General Internal Medicine, 1988. 3(3): p. 306-11.
  67. Kerr, J.S., et al., The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. International Clinical Psychopharmacology, 1992. 7(2): p. 101-8.
  68. Kobak, K.A., et al., Computer-administered clinical rating scales. A review. Psychopharmacology, 1996. 127(4): p. 291-301.
  69. Fones, C.S., G.G. Manfro, and M.H. Pollack, Social phobia: an update. Harvard Review of Psychiatry, 1998. 5(5): p. 247-59.
  70. Naftolowitz, D.F., et al., Response to alcohol in social phobia. Anxiety, 1994. 1(2): p. 96-9.
  71. Nunes, E.V., P.J. McGrath, and F.M. Quitkin, Treating anxiety in patients with alcoholism. Journal of Clinical Psychiatry, 1995. 56 Suppl 2: p. 3-9.
  72. Annemans, Economic Evaluation of Campral (Acamprosate) Compared to Placebo in Maintaining Abstinence in Alcohol-Dependent Patients. European Addiction Research, 2000. 6: p. 71-78.
  73. Goisman, R.M., M.G. Warshaw, and M.B. Keller, Psychosocial treatment prescriptions for generalized anxiety disorder, panic disorder, and social phobia, 1991-1996. American Journal of Psychiatry, 1999. 156(11): p. 1819-21.
  74. Davis, L.L., et al., Nefazodone treatment for chronic posttraumatic stress disorder: an open trial. Journal of Clinical Psychopharmacology, 2000. 20(2): p. 159-64.
  75. Wu, L.T., A.C. Kouzis, and P.J. Leaf, Influence of comorbid alcohol and psychiatric disorders on utilization of mental health services in the National Comorbidity Survey. American Journal of Psychiatry, 1999. 156(8): p. 1230-6.
  76. Whitfield, J.B., Monoamine oxidase: associations with alcohol dependence, smoking and other measures of psychopathology. Psychological Medicine, 2000. 30: p. 443-454.
  77. O'Hare, T.M., Alcohol expectancies and social anxiety in male and female undergraduates. Addictive Behaviors, 1990. 15(6): p. 561-6.
  78. Leshner, A.I., Drug abuse and addiction treatment research. The next generation [comment]. Archives of General Psychiatry, 1997. 54(8): p. 691-4.
  79. Lecrubier, Y. and E. Weiller, Comorbidities in social phobia. International Clinical Psychopharmacology, 1997. 12 Suppl 6: p. S17-21.
  80. Preuss, U.W. and M. Soyka, Paroxetine treatment in alcohol amnestic disorder [letter]. Journal of Neuropsychiatry & Clinical Neurosciences, 1999. 11(2): p. 286-7.
  81. Lotufo-Neto, F. and V. Gentil, Alcoholism and phobic anxiety--a clinical-demographic comparison. Addiction, 1994. 89(4): p. 447-53.
  82. McLellan, A.T., et al., The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment, 1992. 9(3): p. 199-213.
  83. Heimberg, R.G., et al., Psychometric properties of the Liebowitz Social Anxiety Scale. Psychological Medicine, 1999. 29(1): p. 199-212.
  84. Valdespino-Gomez, Long-term Obligations to Human Subjects in Clinical Trials. JAMA, 2000. 284(8).
  85. Maurel, S., J. De Vry, and R. Schreiber, Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats. Alcohol, 1999. 17(3): p. 195-201.
  86. Ringold, A.L., Paroxetine efficacy in social phobia [letter; comment]. Journal of Clinical Psychiatry, 1994. 55(8): p. 363-4.
  87. Judd, L.L., Social phobia: a clinical overview. Journal of Clinical Psychiatry, 1994. 55 Suppl: p. 5-9.
  88. Kathiramalainathan, Inhibition of Cytochrome P450 2D6 Modifies Codeine Abuse Liability. Journal of Clinical Psychopharmacology, 2000. 20(4): p. 435-444.
  89. Zimmet, S.V., et al., Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. Journal of Clinical Psychopharmacology, 2000. 20(1): p. 94-8.
  90. Wells, J.C., et al., Risk factors for the incidence of social phobia as determined by the Diagnostic Interview Schedule in a population-based study. Acta Psychiatrica Scandinavica, 1994. 90(2): p. 84-90.
  91. Mannuzza, S., et al., Generalized social phobia. Reliability and validity. Archives of General Psychiatry, 1995. 52(3): p. 230-7.
  92. Kushner, M.G., Relationship between alcohol problems and anxiety disorders [letter; comment]. American Journal of Psychiatry, 1996. 153(1): p. 139-40.
  93. Haywood, T.W., et al., Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders [see comments]. American Journal of Psychiatry, 1995. 152(6): p. 856-61.
  94. Stravynski, A. and D. Greenberg, The treatment of social phobia: a critical assessment. Acta Psychiatrica Scandinavica, 1998. 98(3): p. 171-81.
  95. Hindmarch, I. and C. Harrison, The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity related to car driving. Acta Psychiatrica Scandinavica, Supplementum, 1989. 350: p. 45.
  96. Strakowski, S.M., et al., Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. Journal of Clinical Psychiatry, 1998. 59(9): p. 465-71.
  97. Daoust, M., et al., Ethanol intake and 3H-serotonin uptake. II: A study in alcoholic patients using platelets 3H-paroxetine binding. Life Sciences, 1991. 48(20): p. 1977-83.
  98. Whitfield, J.B. and N.G. Martin, Alcohol consumption and alcohol pharmacokinetics: interactions within the normal population. Alcoholism: Clinical & Experimental Research, 1994. 18(2): p. 238-43.
  99. Stein, M.B., et al., Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. American Journal of Psychiatry, 1999. 156(5): p. 756-60.
  100. Lecrubier, Y., Comorbidity in social anxiety disorder: impact on disease burden and management. Journal of Clinical Psychiatry, 1998. 59 Suppl 17: p. 33-8.
  101. Versiani, M., R. Amrein, and S.A. Montgomery, Social phobia: long-term treatment outcome and prediction of response--a moclobemide study. International Clinical Psychopharmacology, 1997. 12(5): p. 239-54.
  102. Norton, G.R., et al., Panic disorder or social phobia: which is worse? Behaviour Research & Therapy, 1996. 34(3): p. 273-6.
  103. Schuckit, M.A., et al., The prevalence of major anxiety disorders in relatives of alcohol dependent men and women. Journal of Studies on Alcohol, 1995. 56(3): p. 309-17.
  104. Ballenger, J.C., Current treatments of the anxiety disorders in adults. Biological Psychiatry, 1999. 46(11): p. 1579-94.
  105. Beedle, Diagnosis and Treatment of Psychiatric Comorbidity in Alcoholics and Drug Addicts. Psychiatric Annals, 1998. 28(12): p. 705-708.
  106. Davidson, J.R., et al., The Brief Social Phobia Scale: a psychometric evaluation. Psychological Medicine, 1997. 27(1): p. 161-6.
  107. Clark, D.B., et al., Systematic assessment of social phobia in clinical practice. Depression & Anxiety, 1997. 6(2): p. 47-61.
  108. Pettinati, H.M., Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Alcoholism: Clinical & Experimental Research, 1996. 20(7 Suppl): p. 23A-29A.
  109. Merikangas, K.R., et al., Co-morbidity and familial aggregation of alcoholism and anxiety disorders. Psychological Medicine, 1998. 28(4): p. 773-88.
  110. Lydiard, R.B., The role of drug therapy in social phobia. Journal of Affective Disorders, 1998. 50 Suppl 1: p. S35-9.
  111. Myrick, H. and K.T. Brady, Social phobia in cocaine-dependent individuals. American Journal on Addictions, 1997. 6(2): p. 99-104.
  112. Bailly, D., et al., Platelet serotonin levels in alcoholic patients: changes related to physiological and pathological factors. Psychiatry Research, 1993. 47(1): p. 57-88.
  113. Gouret, C.J., et al., Biochemical and pharmacological evaluation of the novel antidepressant and serotonin uptake inhibitor 2-(3,4-Dichlorobenzyl)-2-dimethylamino-1-propanol hydrochloride. Arzneimittel-Forschung, 1990. 40(6): p. 633-40.
  114. Kessler, R.C., et al., Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 1994. 51(1): p. 8-19.
  115. Montgomery, S.A., Social phobia: diagnosis, severity and implications for treatment. European Archives of Psychiatry & Clinical Neuroscience, 1999. 249 Suppl 1: p. S1-6.
  116. Hesselbrock, M., et al., A validity study of the SSAGA--a comparison with the SCAN. Addiction, 1999. 94(9): p. 1361-70.
  117. Regier, D.A., et al., Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study [see comments]. JAMA, 1990. 264(19): p. 2511-8.
  118. Magee, W.J., et al., Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Archives of General Psychiatry, 1996. 53(2): p. 159-68.
  119. Prescott, C.A., et al., Predictors of problem drinking and alcohol dependence in a population-based sample of female twins. Journal of Studies on Alcohol, 1997. 58(2): p. 167-81.
  120. Thomas, S.E., A.K. Thevos, and C.L. Randall, Alcoholics with and without social phobia: a comparison of substance use and psychiatric variables. Journal of Studies on Alcohol, 1999. 60(4): p. 472-9.
  121. Kranzler, Medications for Alcohol Dependence - New Vistas. JAMA, 2000. 284(8).
  122. Westenberg, H.G., The nature of social anxiety disorder. Journal of Clinical Psychiatry, 1998. 59 Suppl 17: p. 20-6.
  123. Perugi, G., C. Toni, and H.S. Akiskal, Anxious-bipolar comorbidity. Diagnostic and treatment challenges. Psychiatric Clinics of North America, 1999. 22(3): p. 565-83.
  124. Bisserbe, J.C., et al., Social phobia in primary care: level of recognition and drug use. International Clinical Psychopharmacology, 1996. 11 Suppl 3: p. 25-8.
  125. Ozdemir, V., et al., Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Clinical Pharmacokinetics, 1996. 31(5): p. 372-85.
  126. Page, A.C. and G. Andrews, Do specific anxiety disorders show specific drug problems? Australian & New Zealand Journal of Psychiatry, 1996. 30(3): p. 410-4.
  127. Toneatto, Diagnostic Subgroups within a Sample of Comorbid Substance Abusers: Correlates and Characteristics. The American Journal on Addictions, 2000. 9: p. 253-264.
  128. Allgulander, C., Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatrica Scandinavica, 1999. 100(3): p. 193-8.
  129. Ho, A.P., et al., Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. American Journal of Psychiatry, 1999. 156(11): p. 1765-70.
  130. Marshall, J.R., Comorbidity and its effects on panic disorder. Bulletin of the Menninger Clinic, 1996. 60(2 Suppl A): p. A39-53.
  131. Nutt, D.J., C.J. Bell, and A.L. Malizia, Brain mechanisms of social anxiety disorder. Journal of Clinical Psychiatry, 1998. 59 Suppl 17: p. 4-11.
  132. Connor, K.M., et al., Social phobia: issues in assessment and management. Epilepsia, 1999. 40 Suppl 6: p. S60-5; discussion S73-4.
  133. Tiihonen, J., et al., Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort. American Journal of Psychiatry, 1997. 154(6): p. 840-5.
  134. Lagomasino, I., R. Daly, and A. Stoudemire, Medical assessment of patients presenting with psychiatric symptoms in the emergency setting. Psychiatric Clinics of North America, 1999. 22(4): p. 819-50.
  135. Wilkins, J.N., Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophrenia Bulletin, 1997. 23(2): p. 215-28.
  136. Cournos, F. and K. McKinnon, Substance use and HIV risk among people with severe mental illness. NIDA Research Monograph, 1997. 172: p. 110-29.
  137. Johnson, Age of Onset as a Discriminator Between Alcoholic Subtypes in a Treatment-Seeking Outpatient Population. The American Journal on Addictions, 2000. 9: p. 17-27.
  138. Dixon, L., Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research, 1999. 35 Suppl: p. S93-100.
  139. Pettinati, Role of Serotonin and Serotonin-Selective Pharmacotherapy in Alcohol Dependence. CNS Spectrums, 2000. 5(2): p. 33-46.
  140. Burke, R.S. and R.S. Stephens, Social anxiety and drinking in college students: a social cognitive theory analysis. Clinical Psychology Review, 1999. 19(5): p. 513-30.
  141. Siegfried, N., A review of comorbidity: major mental illness and problematic substance use [see comments]. Australian & New Zealand Journal of Psychiatry, 1998. 32(5): p. 707-17.
  142. Petrakis, I.L., et al., Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction, 2000. 95(2): p. 219-28.
  143. Croop, R.S., E.B. Faulkner, and D.F. Labriola, The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Archives of General Psychiatry, 1997. 54(12): p. 1130-5.
  144. Buckley, P.F., Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. Journal of Substance Abuse Treatment, 1998. 15(2): p. 113-6.
  145. Dixon, L., S. McNary, and A.F. Lehman, Remission of substance use disorder among psychiatric inpatients with mental illness. American Journal of Psychiatry, 1998. 155(2): p. 239-43.
  146. Mueser, K.T., et al., Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophrenia Bulletin, 2000. 26(1): p. 179-92.
  147. RachBeisel, J., J. Scott, and L. Dixon, Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatric Services, 1999. 50(11): p. 1427-34.
  148. Petry, N.M., et al., Give them prizes, and they will come: contingency management for treatment of alcohol dependence. Journal of Consulting & Clinical Psychology, 2000. 68(2): p. 250-7.
  149. Wesson, Naltrexone in the Treatment of Alcohol Dependence and Craving for Alcohol. Newsletter of the California Society of Addiction Medicine, 1995. 22(1).
  150. MM, V., Generalizability of Project Match: a comparison of clients enrolled to those not enrolled in the study at one aftercare site. Drug and Alcohol Dependence, 2000. 59(2): p. 177-82.
  151. Robinson, D., et al., Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 1999. 56(3): p. 241-7.
  152. Strathdee, S.A., et al., Barriers to use of free antiretroviral therapy in injection drug users [see comments]. JAMA, 1998. 280(6): p. 547-9.
  153. Carey, K.B., Challenges in assessing substance use patterns in persons with comorbid mental and addictive disorders. NIDA Research Monograph, 1997. 172: p. 16-32.
  154. Gariti, The relationship between psychopathology and smoking cessation treatment response. Drug & Alcohol Dependence, 2000. 60: p. 267-273.
  155. Lepine, J.P. and A. Pelissolo, Social phobia and alcoholism: a complex relationship. Journal of Affective Disorders, 1998. 50 Suppl 1: p. S23-8.
  156. Ziedonis, Schizophrenia and Substance Abuse, in Dual Diagnosis & Treatment, Kranzler, Editor. 1998, Marcel Dekker: New York. p. 427-465.
  157. Drake, R.E., et al., The course, treatment, and outcome of substance disorder in persons with severe mental illness. American Journal of Orthopsychiatry, 1996. 66(1): p. 42-51.
  158. Hogarty, G.E. and S. Flesher, Developmental theory for a cognitive enhancement therapy of schizophrenia. Schizophrenia Bulletin, 1999. 25(4): p. 677-92.
  159. Lewis, B.A. and H.K. O'Neill, Alcohol expectancies and social deficits relating to problem drinking among college students. Addictive Behaviors, 2000. 25(2): p. 295-9.
  160. Mueser, K.T., A.S. Bellack, and J.J. Blanchard, Comorbidity of schizophrenia and substance abuse: implications for treatment. Journal of Consulting & Clinical Psychology, 1992. 60(6): p. 845-56.
  161. Gitlin, M.J., R.H. Gerner, and M. Rosenblatt, Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacology, 1981. 74(1): p. 51-3.
  162. Desmond, Deaths Among Heroin Users In and Out of Methadone Treatment. Journal of Maintenance in the Addictions, 2000. 1(4): p. 45-61.
  163. Ross, H.E., et al., Diagnosing comorbidity in substance abusers: a comparison of the test-retest reliability of two interviews. American Journal of Drug & Alcohol Abuse, 1995. 21(2): p. 167-85.
  164. Stein, M.B., et al., Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA, 1998. 280(8): p. 708-13.
  165. Saxon, A.J., et al., Disulfiram use in patients with abnormal liver function test results. Journal of Clinical Psychiatry, 1998. 59(6): p. 313-6.
  166. Westenberg, H.G., Facing the challenge of social anxiety disorder. European Neuropsychopharmacology, 1999. 9 Suppl 3: p. S93-9.
  167. Tsuang, J.W., et al., Dual diagnosis treatment for patients with schizophrenia who are substance dependent. Psychiatric Services, 1997. 48(7): p. 887-9.
  168. Litten, R.Z. and J.P. Allen, Advances in development of medications for alcoholism treatment. Psychopharmacology, 1998. 139(1-2): p. 20-33.
  169. Van Ameringen, M., et al., Relationship of social phobia with other psychiatric illness. Journal of Affective Disorders, 1991. 21(2): p. 93-9.
  170. Tinsley, J.A., R.E. Finlayson, and R.M. Morse, Developments in the treatment of alcoholism. Mayo Clinic Proceedings, 1998. 73(9): p. 857-63.
  171. Mueser, K.T., et al., Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bulletin, 1990. 16(1): p. 31-56.
  172. O'Brien, C.P., Recent developments in the pharmacotherapy of substance abuse. Journal of Consulting & Clinical Psychology, 1996. 64(4): p. 677-86.
  173. Ott, Comprehensive Substance Abuse Evaluation, in Clinical Textbook of Addictive Disorders. 1998, Guilford Press: New York. p. 35-70.
  174. Stein, M.B., Medication treatments for panic disorder and social phobia. Depression & Anxiety, 1998. 7(3): p. 134-8.
  175. Altman, C.A., Paroxetine not to blame [letter; comment]. Journal of Analytical Toxicology, 1999. 23(4): p. 297-8.
  176. Noordsy, D.L., et al., Subjective experiences related to alcohol use among schizophrenics [see comments]. Journal of Nervous & Mental Disease, 1991. 179(7): p. 410-4.
  177. Hogarty, G.E. and S. Flesher, Practice principles of cognitive enhancement therapy for schizophrenia. Schizophrenia Bulletin, 1999. 25(4): p. 693-708.
  178. Wiseman, E.J., K.L. Henderson, and M.J. Briggs, Individualized treatment for outpatients withdrawing from alcohol. Journal of Clinical Psychiatry, 1998. 59(6): p. 289-93.
  179. Room, The more drinking, the more fun; but is there a calculus of fun, and should it drive policy? Drug & Alcohol Dependence, 2000. 60: p. 249-250.
  180. Montgomery, S.A., Social phobia: the need for treatment. International Clinical Psychopharmacology, 1997. 12 Suppl 6: p. S3-9.
  181. Bailly, D., et al., Platelet serotonin decrease in alcoholic patients. Acta Psychiatrica Scandinavica, 1990. 81(1): p. 68-72.
  182. Addington, J. and V. Duchak, Reasons for substance use in schizophrenia. Acta Psychiatrica Scandinavica, 1997. 96(5): p. 329-33.
  183. Liebowitz, M.R., Update on the diagnosis and treatment of social anxiety disorder. Journal of Clinical Psychiatry, 1999. 60 Suppl 18: p. 22-6.
  184. Anton, R.F., Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol & Alcoholism. Supplement, 1996. 1: p. 43-53.
  185. Modestin, J. and R. Ammann, Mental disorders and criminal behaviour. British Journal of Psychiatry, 1995. 166(5): p. 667-75.
  186. Maxwell, Naltrexone in the Treatment of Dually-Diagnosed Patients. Journal of Addictive Diseases, 1997. 16(2): p. 125.
  187. Arranz, B., et al., Platelet serotonergic binding sites in alcohol-dependent patients. Alcohol & Alcoholism, 1999. 34(5): p. 726-32.
  188. Volpicelli, J.R., et al., Effect of naltrexone on alcohol "high" in alcoholics. American Journal of Psychiatry, 1995. 152(4): p. 613-5.
  189. Sloan, K.L., Substance Abuse and Psychiatric Illness. The American Journal on Addictions, 1995. 4(1): p. 60-69.
  190. Drake, R.E., et al., Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin, 1990. 16(1): p. 57-67.
  191. Harris, Stimulant Psychosis: Symptom Profile and Acute Clinical Course. The American Journal on Addictions, 2000. 9(1): p. 28-37.
  192. RachBeisel, J., L. Dixon, and J. Gearon, Awareness of substance abuse problems among dually-diagnosed psychiatric inpatients. Journal of Psychoactive Drugs, 1999. 31(1): p. 53-7.
  193. Kirchner, J.E., et al., Diagnosis and management of substance use disorders among inpatients with schizophrenia. Psychiatric Services, 1998. 49(1): p. 82-5.
  194. Merikangas, K.R., et al., Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. British Journal of Psychiatry - Supplement, 1996(30): p. 58-67.
  195. Anton, R.F., What is craving? Models and implications for treatment. Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse & Alcoholism, 1999. 23(3): p. 165-73.
  196. Fowler, I.L., et al., Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin, 1998. 24(3): p. 443-55.
  197. Montgomery, S.A., Implications of the severity of social phobia. Journal of Affective Disorders, 1998. 50 Suppl 1: p. S17-22.
  198. Maglione, M., Correlates of Outpatient Drug Treatment Drop-Out Among Methamphetamine Users. Journal of Psychoactive Drugs, 2000. 32(2): p. 221-228.
  199. Romach, Alcoholism and Anxiety Disorders, in Dual Diagnosis & Treatment. 1998, Marcel Dekker: New York. p. 137-175.
  200. Grant, Theoretical and observed subtypes of DSM-IV alcohol abuse and dependence in a general population sample. Drug & Alcohol Dependence, 2000. 60: p. 287-293.
  201. Swift, R.M., Opioid Antagonists and Alcoholism Treatment. CNS Spectrums, 2000. 5(2): p. 49-57.
  202. Wittchen, H.U. and E. Beloch, The impact of social phobia on quality of life. International Clinical Psychopharmacology, 1996. 11 Suppl 3: p. 15-23.
  203. Brady, K.T., Dual Diagnosis, in The American Psychiatric Press Textbook of Substance Abuse Treatment, Galanter, Editor. 1999, American Psychiatric Press, Inc.: Washington, DC. p. 475-483.
  204. Anglin, M.D., The CSAT Methamphetamine Treatment Project: What Are We Trying to Accomplish? Journal of Psychoactive Drugs, 2000. 32(2): p. 209-210.
  205. Mancini, C. and M.V. Ameringen, Paroxetine in social phobia. Journal of Clinical Psychiatry, 1996. 57(11): p. 519-22.
  206. Barbey, J.T. and S.P. Roose, SSRI safety in overdose. Journal of Clinical Psychiatry, 1998. 59 Suppl 15: p. 42-8.
  207. Swift, R.M., Drug therapy for alcohol dependence. New England Journal of Medicine, 1999. 340(19): p. 1482-90.
  208. Greist, J.H., The diagnosis of social phobia. Journal of Clinical Psychiatry, 1995. 56 Suppl 5: p. 5-12.
  209. Buckley, P.F., Substance abuse in schizophrenia: a review. Journal of Clinical Psychiatry, 1998. 59 Suppl 3: p. 26-30.
  210. Verebey, Laboratory Testing, in Clinical Textbook of Addictive Disorders. 1998, Guilford Press: New York. p. 71-88.
  211. Swift, R.M., Effect of naltrexone on human alcohol consumption. Journal of Clinical Psychiatry, 1995. 56 Suppl 7: p. 24-9.
  212. Kallmen, H. and R. Gustafson, Alcohol and disinhibition. European Addiction Research, 1998. 4(4): p. 150-62.
  213. O'Brien, C.P., Opioids: Antagonists and Partial Agonists, in The American Psychiatric Press Textbook of Substance Abuse Treatment, Galanter, Editor. 1999, American Psychiatric Press, Inc.: Washington, DC. p. 281-294.
  214. Sheehan, D.V., et al., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 1998. 59 Suppl 20: p. 22-33;quiz 34-57.
  215. Poikolainen, K., Risk Factors for Alcohol Depencence: a Case-Control Study. Alcohol and alcoholism, 2000. 35(2): p. 190-196.
  216. Brecht, M.-L., Predictors of Relapse After Treatment for Methamphetamine Use. Journal of Psychoactive Drugs, 2000. 32(2): p. 211-220.
  217. Rawson, R., Methamphetamine and Cocaine Users: Differences in Characteristics and Treatment Retention. Journal of Psychoactive Drugs, 2000. 32(2): p. 233-238.
  218. Johnson, J., Cost-effectiveness of mental health services for persons with a dual diagnosis: a literature review and the CCMHCP. The Cost-Effectiveness of Community Mental Health Care for Single and Dually Diagnosed Project. Journal of Substance Abuse Treatment, 2000. 18(2): p. 119-27.
  219. Domier, C., A Comparison of Injecting and Noninjecting Methamphetamine Users. Journal of Psychoactive Drugs, 2000. 32(2): p. 229-232.
  220. Dixon, L., et al., The association of medical comorbidity in schizophrenia with poor physical and mental health. Journal of Nervous & Mental Disease, 1999. 187(8): p. 496-502.
  221. Preston, K.L., A. Umbricht, and D.H. Epstein, Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Archives of General Psychiatry, 2000. 57(4): p. 395-404.
  222. Anand, A., et al., Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Archives of General Psychiatry, 2000. 57(3): p. 270-6.
  223. Devlin, M.J., S.Z. Yanovski, and G.T. Wilson, Obesity: what mental health professionals need to know [see comments]. American Journal of Psychiatry, 2000. 157(6): p. 854-66.
  224. Files, F.J., C.E. Denning, and H.H. Samson, Effects of the atypical antipsychotic remoxipride on alcohol self-administration. Pharmacology, Biochemistry & Behavior, 1998. 59(2): p. 281-5.
  225. Dieperink, E., M. Willenbring, and S.B. Ho, Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. American Journal of Psychiatry, 2000. 157(6): p. 867-76.
  226. Smart, Drinking and heavy drinking by students in 18 countries. Drug & Alcohol Dependence, 2000. 60: p. 315-318.
  227. Nierenberg, A.A., et al., Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry, 2000. 157(9): p. 1423-8.
  228. Stein, M.B., Disability and Quality of Life in Social Phobia: Epidemiologic Findings. Am. J. Psychiatry, 2000. 157(10): p. 1606-1613.
  229. White, Naltrexone Treatment for a 3-Year-Old Boy With Self-Injurious Behavior. Am J Psychiatry, 2000. 157(10): p. 1574-1582.
  230. Rounsaville, B.J., et al., Personality disorders in substance abusers: relation to substance use. Journal of Nervous & Mental Disease, 1998. 186(2): p. 87-95.
  231. Chilcoat, H.D. and N. Breslau, Pathways from ADHD to early drug use. Journal of the American Academy of Child & Adolescent Psychiatry, 1999. 38(11): p. 1347-54.
  232. Leshner, A.I. and G.F. Koob, Drugs of abuse and the brain. Proceedings of the Association of American Physicians, 1999. 111(2): p. 99-108.
  233. Grant, I., Alcohol and the brain: neuropsychological correlates. Journal of Consulting & Clinical Psychology, 1987. 55(3): p. 310-24.
  234. Sobell, L., M. Sobell, and T. Nirenberg, Behavioral Assessment and Treatment Planning wth Alcohol and Drug Abusers: A Review With an Emphasis on Clinical Application. Clinical Psychology Review, 1988. 8: p. 19-44.
  235. Drake, R.E., et al., New Hampshire's specialized services for the dually diagnosed. New Directions for Mental Health Services, 1991(50): p. 57-67.
  236. Fischer, E.P., R.R. Owen, and B.J. Cuffel, Substance abuse, community service use, and symptom severity of urban and rural residents with schizoprhenia. Psychiatric Services, 1996. 47(9): p. 980-4.
  237. Bartels, S.J., et al., Substance abuse in schizophrenia: service utilization and costs. Journal of Nervous & Mental Disease, 1993. 181(4): p. 227-32.
  238. Petti, T.A., P.J. Cornely, and A. McIntyre, A consultative study as a catalyst for improving mental health services for rural children and adolescents. Hospital & Community Psychiatry, 1993. 44(3): p. 262-5.
  239. Chalifoux, Z., et al., Mental health services for rural elderly: innovative service strategies. Community Mental Health Journal, 1996. 32(5): p. 463-80.
  240. Van Hook, M.P., Challenges to identifying and treating women with depression in rural primary care. Social Work in Health Care, 1996. 23(3): p. 73-92.
  241. O'Hare, T., Mental health problems and alcohol abuse: co-occurrence and gender differences. Health & Social Work, 1995. 20(3): p. 207-14.
  242. Sheldon-Keller, A.E., et al., The provision of services for rural youth with serious emotional and behavioral problems: Virginia's Comprehensive Services Act. Community Mental Health Journal, 1996. 32(5): p. 481-95.
  243. Yurkovich, E., J. Buehler, and T. Smyer, Loss of control and the chronic mentally ill in a rural day-treatment center. Perspectives in Psychiatric Care, 1997. 33(3): p. 33-9.
  244. Farrell, S.P., J.R. Koch, and M. Blank, Rural and urban differences in continuity of care after state hospital discharge. Psychiatric Services, 1996. 47(6): p. 652-4.
  245. Boyd, M.R. and E.J. Hauenstein, Psychiatric assessment and confirmation of dual disorders in rural substance abusing women. Archives of Psychiatric Nursing, 1997. 11(2): p. 74-81.
  246. Husted, J., S.A. Wentler, and A. Bursell, The effectiveness of community support programs for persistently mentally ill in rural areas. Community Mental Health Journal, 1994. 30(6): p. 595-600.
  247. Bushy, A., When your client lives in a rural area. Part I: Rural health care delivery issues. Issues in Mental Health Nursing, 1994. 15(3): p. 253-66.
  248. Bushy, A., When your client lives in a rural area. Part II: Rural professional practice--considerations for nurses providing mental health care. Issues in Mental Health Nursing, 1994. 15(3): p. 267-76.
  249. Hollingsworth, E.J., M.K. Pitts, and D. McKee, Staffing patterns in rural community support programs. Hospital & Community Psychiatry, 1993. 44(11): p. 1076-81.
  250. Kales, J.P., et al., Mental illness and substance use among sheltered homeless persons in lower-density population areas. Psychiatric Services, 1995. 46(6): p. 592-5.
  251. Lachance, K.R. and A.B. Santos, Modifying the PACT model: preserving critical elements. Psychiatric Services, 1995. 46(6): p. 601-4.
  252. Peele, S., What treatment for addiction can do and what it can't; what treatment for addiction should do and what it shouldn't. Journal of Substance Abuse Treatment, 1985. 2(4): p. 225-8.
  253. Bukstein, O.G., D.A. Brent, and Y. Kaminer, Comorbidity of substance abuse and other psychiatric disorders in adolescents. [see comments]. American Journal of Psychiatry, 1989. 146(9): p. 1131-41.
  254. Ridgely, M.S., H.H. Goldman, and M. Willenbring, Barriers to the care of persons with dual diagnoses: organizational and financing issues. Schizophrenia Bulletin, 1990. 16(1): p. 123-32.
  255. Lambert, D. and D. Hartley, Linking primary care and rural psychiatry: where have we been and where are we going? Psychiatric Services, 1998. 49(7): p. 965-7.
  256. McHugo, G.J., et al., A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. Journal of Nervous & Mental Disease, 1995. 183(12): p. 762-7.
  257. Drake, R.E., et al., Treatment of substance abuse in severely mentally ill patients. Journal of Nervous & Mental Disease, 1993. 181(10): p. 606-11.
  258. Kane, C.F. and J.M. Ennis, Health care reform and rural mental health: severe mental illness. Community Mental Health Journal, 1996. 32(5): p. 445-62.
  259. Shelton, D.A. and R. Frank, Rural mental health coverage under health care reform. Community Mental Health Journal, 1995. 31(6): p. 539-52.
  260. Carey, K.B., Substance use reduction in the context of outpatient psychiatric treatment: a collaborative, motivational, harm reduction approach. [see comments]. Community Mental Health Journal, 1996. 32(3): p. 291-306; discussion 307-10.
  261. Bartels, S.J., R.E. Drake, and M.A. Wallach, Long-term course of substance use disorders among patients with severe mental illness. Psychiatric Services, 1995. 46(3): p. 248-51.
  262. Kazdin, A.E., Parent management training: evidence, outcomes, and issues. Journal of the American Academy of Child & Adolescent Psychiatry, 1997. 36(10): p. 1349-56.
  263. Luczynska, C. and K. Wilson, The clinical significance of the effects of cigarette smoking on drug disposition. Methods & Findings in Experimental & Clinical Pharmacology, 1983. 5(7): p. 479-87.
  264. Masand, P.S., et al., Major depression and irritable bowel syndrome: is there a relationship? Journal of Clinical Psychiatry, 1995. 56(8): p. 363-7.
  265. Bollerud, K., A model for the treatment of trauma-related syndromes among chemically dependent inpatient women. Journal of Substance Abuse Treatment, 1990. 7(2): p. 83-7.
  266. Test, M.A., et al., Substance use in young adults with schizophrenic disorders. Schizophrenia Bulletin, 1989. 15(3): p. 465-76.
  267. Tobin, J.J. and J. Friedman, Spirits, shamans, and nightmare death: survivor stress in a Hmong refugee. American Journal of Orthopsychiatry, 1983. 53(3): p. 439-48.
  268. Wagenfeld, M.O., et al., Mental health service delivery in rural areas: organizational and clinical issues. NIDA Research Monograph, 1997. 168: p. 418-37.
  269. Kane, R.L., J. Bartlett, and S. Potthoff, Integrating an outcomes information system into managed care for substance abuse. Behavioral Healthcare Tomorrow, 1994. 3(3): p. 57-61.
  270. Preston, J., F.W. Brown, and B. Hartley, Using telemedicine to improve health care in distant areas. [see comments]. Hospital & Community Psychiatry, 1992. 43(1): p. 25-32.
  271. Brown, F.W., Rural telepsychiatry. [see comments]. Psychiatric Services, 1998. 49(7): p. 963-4.
  272. Miller, N., R. Swift, and M. Gold, Health Care Economics for Integrated Addiction Treatment in Clinical Settings. Psychiatric Annals, 1998. 28.
  273. Bartels, S.J. and W.N. Thomas, Lessons From a Pilot Residential Treatment Program for People with Dual Diagnosis of Severe Mental Illness and Substance Use Disorder. Psychosocial Rehabilitation Journal, 1991. 15(2): p. 19-30.
  274. Smyth, N.J., Motivating Persons with Dual Disorders: A Stage Approach. Families in Society, 1996.
  275. Nicholson, J., E.M. Sweeney, and J.L. Geller, Mothers with mental illness: I. The competing demands of parenting and living with mental illness. Psychiatric Services, 1998. 49(5): p. 635-42.
  276. Lamb, H.R. and L.E. Weinberger, Persons with severe mental illness in jails and prisons: a review. [see comments]. Psychiatric Services, 1998. 49(4): p. 483-92.
  277. Drake, R.E., et al., Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. American Journal of Orthopsychiatry, 1998. 68(2): p. 201-15.
  278. Ziedonis, D.M. and W. Fisher, Assessment and Treatment of Comorbid Substance Abuse in Individuals with Schizophrenia. Psychiatric Annals, 1994. 24(9): p. 447-483.
  279. Steadman, H.J., et al., Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. [see comments]. Archives of General Psychiatry, 1998. 55(5): p. 393-401.
  280. Clark, R.E., Family support for persons with dual disorders. New Directions for Mental Health Services, 1996(70): p. 65-78.
  281. Yuen, E.J., J.L. Gerdes, and J.J. Gonzales, Patterns of rural mental health care. An exploratory study. [see comments]. General Hospital Psychiatry, 1996. 18(1): p. 14-21.
  282. Mueser, K.T., et al., Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia. Journal of Abnormal Psychology, 1997. 106(3): p. 473-7.
  283. Minkoff, K., Program components of a comprehensive integrated care system for serious mentally ill patients with substance disorders. New Directions for Mental Health Services, 1991(50): p. 13-27.
  284. Clark, R.E., S.K. Ricketts, and G.J. McHugo, Legal system involvement and costs for persons in treatment for severe mental illness and substance use disorders. Psychiatric Services, 1999. 50(5): p. 641-7.
  285. Veysey, B.M., et al., In search of the missing linkages: continuity of care in U.S. jails. Behavioral Sciences & the Law, 1997. 15(4): p. 383-97.
  286. Lehman, A.F., Heterogeneity of person and place: assessing co-occurring addictive and mental disorders. American Journal of Orthopsychiatry, 1996. 66(1): p. 32-41.
  287. Drake, R.E., A.I. Alterman, and S.R. Rosenberg, Detection of substance use disorders in severely mentally ill patients. Community Mental Health Journal, 1993. 29(2): p. 175-92; discussion 193-4.
  288. Kandel, D.B., et al., Psychiatric disorders associated with substance use among children and adolescents: findings from the Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) Study. Journal of Abnormal Child Psychology, 1997. 25(2): p. 121-32.
  289. Weller, E.B., R.A. Weller, and M.A. Fristad, Bipolar disorder in children: misdiagnosis, underdiagnosis, and future directions. Journal of the American Academy of Child & Adolescent Psychiatry, 1995. 34(6): p. 709-14.
  290. Grizenko, N. and C. Fisher, Review of studies of risk and protective factors for psychopathology in children. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie, 1992. 37(10): p. 711-21.
  291. Olfson, M., et al., Mental disorders and disability among patients in a primary care group practice. American Journal of Psychiatry, 1997. 154(12): p. 1734-40.
  292. Adler, D.A., et al., Patient-based health status assessments in an outpatient psychiatry setting. Psychiatric Services, 2000. 51(3): p. 341-8.
  293. Roy, A., Risk factors for suicide in psychiatric patients. Archives of General Psychiatry, 1982. 39(9): p. 1089-95.
  294. Dixon, L., et al., Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophrenia Bulletin, 1990. 16(1): p. 69-79.
  295. Pristach, C.A. and C.M. Smith, Medication compliance and substance abuse among schizophrenic patients. Hospital & Community Psychiatry, 1990. 41(12): p. 1345-8.
  296. Rohsenow, D.J., Social anxiety, daily moods, and alcohol use over time among heavy social drinking men. Addictive Behaviors, 1982. 7(3): p. 311-5.
  297. Stoffelmayr, B.E., B.E. Mavis, and R.M. Kasim, The longitudinal stability of the Addiction Severity Index. Journal of Substance Abuse Treatment, 1994. 11(4): p. 373-8.
  298. Greenberg, A. and R. Judem-Cautin, Group Treatment of the Psyhiatrically Impaired Substance Abuser. Professional Counselor, 1990: p. 49-56.
  299. Carey, K.B., Emerging treatment guidelines for mentally ill chemical abusers. Hospital & Community Psychiatry, 1989. 40(4): p. 341-2.
  300. Batki, S.L. and S.J. Ferrando, Diagnosis and Treatment of Substance use Disorders in Patients with HIV Infection. International Review of Psychiatry, 1996. 8: p. 245-252.
  301. Batki, S.L., Drug abuse, psychiatric disorders, and AIDS. Dual and triple diagnosis. Western Journal of Medicine, 1990. 152(5): p. 547-52.
  302. Schuckit, M.A., Alcoholism and other psychiatric disorders. Hospital & Community Psychiatry, 1983. 34(11): p. 1022-7.
  303. Birtchnell, J., Psychotherapeutic considerations in the management of the suicidal patient. American Journal of Psychotherapy, 1983. 37(1): p. 24-36.
  304. Alpert, M. and K.N. Silvers, Perceptual characteristics distinguishing auditory hallucinations in schizophrenia and acute alcoholic psychoses. American Journal of Psychiatry, 1970. 127(3): p. 298-302.
  305. Westermeyer, J., Research on treatment of drinking problems. Importance of cultural factors. Journal of Studies on Alcohol - Supplement, 1981. 9: p. 44-59.
  306. Greenley, J.R., Social factors, mental illness, and psychiatric care: recent advances from a sociological perspective. Hospital & Community Psychiatry, 1984. 35(8): p. 813-20.
  307. Ronan, L., Alcohol-Related Health Risks Among Black Americans. Alcohol Health & Research World, 1986: p. 36-39.
  308. Thomas, R.K., The history of North American Indian alcohol use as a community-based phenomenon. Journal of Studies on Alcohol - Supplement, 1981. 9: p. 29-39.
  309. Parson, E.R., Post-Traumatic Psychocultural Therapy (PTpsyCT): Integration of Trauma and Shattering Social Labels of the Self. Journal of Contemporary Psychotherapy, 1990. 20(4): p. 238-258.
  310. London, H. and W. Devore, Layers of Understanding: Counseling Ethnic Minority Families. Family Relations, 1988. 37: p. 310-314.
  311. Herz, M.I., Recognizing and preventing relapse in patients with schizophrenia. Hospital & Community Psychiatry, 1984. 35(4): p. 344-9.
  312. Anthony, W.A. and M. Farkas, A client outcome planning model for assessing psychiatric rehabilitation interventions. Schizophrenia Bulletin, 1982. 8(1): p. 13-38.
  313. Morgan, C.O., J. Rigaud, and S. Taylor, Treatment for Sexual Trauma. Professional Counselor, 1990: p. 31-66.
  314. Zung, W.W., Suicide prevention by suicide detection. Psychosomatics, 1979. 20(3): p. 149.
  315. DiFonzo, P.J. and L.M. Giordano, Psychiatric Crisis or Organic Illness. Emergency Medicine, 1988: p. 26-36.
  316. Chutuape, M.A. and H. de Wit, Preferences for ethanol and diazepam in anxious individuals: an evaluation of the self-medication hypothesis. Psychopharmacology, 1995. 121(1): p. 91-103.
  317. Cornelius, J.R., et al., Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacology Bulletin, 1997. 33(1): p. 165-70.
  318. Davidson, K.M., Diagnosis of depression in alcohol dependence: changes in prevalence with drinking status. British Journal of Psychiatry, 1995. 166(2): p. 199-204.
  319. DuPont, R.L. and C.M. DuPont, The treatment of anxiety: realistic expectations and risks posed by controlled substances. Journal of Law, Medicine & Ethics, 1994. 22(3): p. 206-14.
  320. Goldenberg, I.M., et al., Specificity of substance use in anxiety-disordered subjects. Comprehensive Psychiatry, 1995. 36(5): p. 319-28.
  321. Hasin, D.S., et al., The effects of major depression on Alcoholism. The American Journal on Addictions, 1996. 5(2): p. 144-156.
  322. Hasin, D.S., J. Endicott, and M.B. Keller, RDC alcoholism in patients with major affective syndromes: two-year course. American Journal of Psychiatry, 1989. 146(3): p. 318-23.
  323. Husband, S.D., et al., Decline in self-reported dysphoria after treatment entry in inner-city cocaine addicts. Journal of Consulting & Clinical Psychology, 1996. 64(1): p. 221-4.
  324. Marlowe, D.B., et al., Psychiatric Comorbidity in Cocaine Dependence. The American Journal on Addictions, 1995. 4(1): p. 70-81.
  325. Mason, B.J., et al., A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. [see comments]. JAMA, 1996. 275(10): p. 761-7.
  326. McCance-Katz, E.F., J. Leal, and R.S. Schottenfeld, Attention Deficit Hyperactivity Disorder and Cocaine Abuse. The American Journal on Addictions, 1995. 4(1): p. 88-91.
  327. Nunes, E.V., et al., Predictors of Antidepressant Response in Depressed Alcoholic Patients. The American Journal on Addictions, 1996. 5(4): p. 308-312.
  328. Feinman, J.A. and D.L. Dunner, The effect of alcohol and substance abuse on the course of bipolar affective disorder. Journal of Affective Disorders, 1996. 37(1): p. 43-9.
  329. Biederman, J., et al., Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. [see comments]. American Journal of Psychiatry, 1995. 152(11): p. 1652-8.
  330. Gretch, D.R., Diagnostic tests for hepatitis C. Hepatology, 1997. 26(3 Suppl 1): p. 43S-47S.
  331. Davis, G.L. and J.Y. Lau, Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology, 1997. 26(3 Suppl 1): p. 122S-127S.
  332. Schalm, S.W., G. Fattovich, and J.T. Brouwer, Therapy of hepatitis C: patients with cirrhosis. Hepatology, 1997. 26(3 Suppl 1): p. 128S-132S.
  333. Perrillo, R.P., The Role of Liver Biopsy in Hepatitis C. Hepatology, 1997. 26(3): p. 57S-61S.
  334. Lok, A.S. and N.T. Gunaratnam, Diagnosis of hepatitis C. Hepatology, 1997. 26(3 Suppl 1): p. 48S-56S.
  335. Seeff, L.B., Natural history of hepatitis C. Hepatology, 1997. 26(3 Suppl 1): p. 21S-28S.
  336. Schiff, E.R., Hepatitis C and alcohol. Hepatology, 1997. 26(3 Suppl 1): p. 39S-42S.
  337. Marcellin, P., S. Levy, and S. Erlinger, Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology, 1997. 26(3 Suppl 1): p. 133S-136S.
  338. Hoofnagle, J.H., Hepatitis C: the clinical spectrum of disease. Hepatology, 1997. 26(3 Suppl 1): p. 15S-20S.
  339. Dienstag, J.L., Sexual and perinatal transmission of hepatitis C. Hepatology, 1997. 26(3 Suppl 1): p. 66S-70S.
  340. Dusheiko, G., Side effects of alpha interferon in chronic hepatitis C. Hepatology, 1997. 26(3 Suppl 1): p. 112S-121S.
  341. Purcell, R., The hepatitis C virus: overview. Hepatology, 1997. 26(3 Suppl 1): p. 11S-14S.
  342. Koff, R.S., Therapy of hepatitis C: cost-effectiveness analysis. Hepatology, 1997. 26(3 Suppl 1): p. 152S-155S.
  343. Van Itallie, T.B. and B.T. Burton, National Institutes of Health consensus development conference on surgical treatment of morbid obesity. Annals of Surgery, 1979. 189(4): p. 455-7.
  344. Hollister, L.E., et al., Aversive effects of naltrexone in subjects not dependent on opiates. Drug & Alcohol Dependence, 1981. 8(1): p. 37-41.
  345. Sternbach, H. and R. State, Antibiotics: neuropsychiatric effects and psychotropic interactions. Harvard Review of Psychiatry, 1997. 5: p. 214-26.
  346. Ferrando, S.J. and S.L. Batki, Substance abuse and HIV infection. New Directions for Mental Health Services, 2000: p. 57-67.
  347. Heinz, A., et al., A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biological Psychiatry, 2000. 47: p. 643-9.
  348. Novick, D.M., The Impact of Hepatitis C Virus Infection on Methadone Maintenance Treatment. The Mount Sinai Journal of Medicine, 2000. 67: p. 437-443.
  349. Alter, M.J., Epidemiology of hepatitis C. Hepatology, 1997. 26: p. 62S-65S.
  350. Cummings, K.J., et al., Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. [see comments]. JAMA, 2001. 285: p. 193-9.
  351. Koff, R., Nonresponse to interferon in chronic hepatitis C: re-treatment redux. [letter; comment]. JAMA, 2001. 285: p. 212-4.
  352. Stephenson, J., Former addicts face barriers to treatment for HCV. JAMA, 2001. 285: p. 1003-5.
  353. Koch, M. and P. Banys, Liver transplantation and opioid dependence. JAMA, 2001. 285: p. 1056-8.
  354. Bravo, A.A., S.G. Sheth, and S. Chopra, Liver biopsy. New England Journal of Medicine, 2001. 344: p. 495-500.
  355. Clarke, S.M. and F.M. Mulcahy, Antiretroviral therapy for drug users. International Journal of STD & AIDS, 2000. 11: p. 627-31.
  356. Lasser, K., et al., Smoking and mental illness: A population-based prevalence study. JAMA, 2000. 284: p. 2606-10.
  357. Betz, C., et al., Could a common biochemical mechanism underlie addictions? Journal of Clinical Pharmacy & Therapeutics, 2000. 25: p. 11-20.
  358. Lindsay, K.L., Therapy of Hepatitis C: Overview. JAMA, 1997. 26: p. 71S-77S.
  359. Kenkel, M.B., Rural Women's Work Group Meets. Rural Health Bulletin, 1996. 3.
  360. Cocores, J.A. and M.S. Gold, Substance Abuse and Sexual Dysfunction. Medical Aspects of Human Sexuality, 1989: p. 22-31.
  361. Batki, S.L. and J.L. Sorenson, Systems of Care for HIV-Infected Injection Drug Users, in The AIDS Knowledge Base, P.T. Cohen, M.A. Sande, and P.A. Volberding, Editors. 1999, Lippencott-Raven Publishers: Philadelphia. p. 355-361.
  362. Ferrando, S.J. and S.L. Batki, HIV Infection: From Dual to Triple Diagnosis, in Dual Diagnosis and Treatment, Kranzler and B.J. Rounsaville, Editors. 1998, Marcel Dekker: New York. p. 503-534.
  363. Leland, J., Alcohol Use and Abuse in Ethnic Minority Women, in Alcohol Problems in Women: Antecedents, Consequences, and Intervention, S.C. Wilsnack and L.J. Beckman, Editors, The Guilford Press: New York. p. 67-95.
  364. Eden, S.L. and R.J. Aguilar, The Hispanic Chemically Dependent Client: Considerations for Diagnosis and Treatment, in Alcoholism & Substance Abuse in Special Populations, G.W. Lawson and A.W. Lawson, Editors, Aspen Publishers, Inc.: Rockville. p. 205-222.
  365. Phelps, J. and A. Nourse, Individual Addictiveness Profile: A Self Administered Test, in The Hidden Addiction and How to Get Free. 1986, Little, Brown.
  366. Carey, K.B., Treatment of the mentally ill chemical abuser: description of the Hutchings Day Treatment Program. Psychiatric Quarterly, 1989. 60: p. 303-16.
  367. Carey, K.B., B.A. Meisler, and M.P. Carey, Problem Solving Training with Mentally ill Chemical Abusers: A Training Manual.
  368. McKelvy, M.J., J.S. Kane, and K. Kellison, Substance abuse and mental illness. Double trouble. Journal of Psychosocial Nursing & Mental Health Services, 1987. 25: p. 20-5.
  369. Sawyer, D. and P.G. Beeson, Rural Mental Health: 2000 & Beyond. 2000, The National Association for Rural Mental Health: Minnesota. p. 1-14.
  370. Workgroup, O.O.I., Co-Occuring Psychiatric and Addictive Disorders: PRINCIPLES and VALUES of care for persons with C-Occuring Psychiatric and Addictive Disorders. 1997, New York State Department of Mental Hygiene Inter-Office Coordinating Council. p. 11-13.
  371. Initiative, T.C.s., Report of a Forum on Education for Seriously Emotiona;;y Disturbed Children and Youth. 1992, State Communities Aid Association: Albany, NY. p. 2-10.
  372. Carlin, A.S., Neuropsychological Consequences of Drug Abuse, in Neuropsychological Assessment of Neuropsychiatric Disorders. p. 478-497.
  373. Smith, M. and K.C. Buckwalter, Mental healthcare for rural seniors. An outreach program in Cedar Rapids, IA, uses an integrated approach to break down barriers to care. Health Progress, 1993. 74(2): p. 52-6.
  374. Osher, F.C., J. Johnson, and M.S. Ridgely, Integrating Clinnical Care for People with Co-Occuring Mental Health and Substance Use Disorders. 1995, University of Maryland at Baltimore Center for Mental Health Services Research State of Maryland, Mental Hygiene Administration: Baltimore.
  375. Mehr, J., Professional Curriculum for MISA/MICA. 1997, Managed Care Initiative Panel on Co-Occuring Disorders.
  376. Treatment of Acute Reactions. The Medical Letter, 1987. 29(748): p. 83-85.
  377. Blum, K., Glossary of Street and Specific Terms, in Handbook of Abusable Drugs. 1984, Gardener Press Inc.: New York. p. 677-685.
  378. Schuckit, M., Cocaine: An Update, in Drug Abuse & Alcoholism Newsletter. 1988.
  379. Meyer, J. and C.M. Fink, Psychiatric Symptoms From Prescription Medications. Professional Psychology: Research and Practice, 1989. 20(2): p. 90-96.
  380. Brown, V.B. and T.E. Backer, The Substance-Abusing Mentally Ill Patient: Challenges for Professional Education and Training. Psychosocial Rehabilitation Journal, 1988. 12(1): p. 43-54.
  381. Wanck, B., Addiction and Mental Illness: Assessing the Difference. Medical Update, 1987. 3(1).
  382. Carey, K.B., Emerging Treatment Guidelines for Mentally Ill Chemical Abusers. Hospital & Community Psychiatry, 1989. 40(4): p. 341-349.
  383. Adler, T., Addicts learn to resist their cocaine cravings, in Science. 1989. p. 13.
  384. Gross, J., Speed's Gain in Use Could Rival Crack, Drug Experts Warn, in The New York Times. 1988: New York.
  385. Borison, R.L., et al., Standard and Novel Antupsychotic Drugs in Schizophrenia, in Contemporary Issues in the Treatment of Schizophrenia. p. 247-293.
  386. Cooper, S., Urban Bias Creating Faulty Assumptions about Rural/Frontier Areas Voice from the Field. Rural Mental Health.
  387. Schuckit, M., Nicotine, Withdrawal, and it's Treatment. Drug Abuse & Alcoholism Newsletter, 1988. 17(6).
  388. Schuckit, M., Drug Testing: What it Can and Cannot Do. Drug Abuse & Alcoholism Newsletter, 1990. 19(2).
  389. Manno, J.E., Urine testing for drugs of abuse. NIDA Research Monograph, 1986. 73: p. 1-114.
  390. Pilette, W.L., Caffeine: psychiatric grounds for concern. Journal of Psychosocial Nursing & Mental Health Services, 1983. 21(8): p. 19-24.
  391. Practical Tips For MICA Groups., Mentally Ill Chemical Abuse Trainig Project: New York.
  392. Transference.
  393. Countertransference.
  394. A Sampling of Strategies for Responding to Difficult Clients.
  395. Some Types of Client-Generated Resistance.
  396. Fletcher, E.C., Reentering School-Life After Treatment. Adolescent Counselor, 1992: p. 23-24.
  397. Gorman, C., Why It's So Hard to Quit Smoking, in Time. 1988. p. 56.
  398. Tung, T., Psychiatric Care for Southeast Asians: How Different is Different?, in Southeast Asian Mental Health: Treatment, Prevention, Services, Training, and Research, T.C. Owen, Editor. 1985: Falls Church, VA. p. 5-40.
  399. Fellios, P.G., Alcoholism in Women: Causes, Treatment, and Prevention, in Alcoholism and Substance Abuse in Special Populations. p. 11-36.
  400. Donovan, B.R., Evaluation of Substance Abuse Prevention Programs for Minority Youth: Teleconference Presentation Outline., New York State Office of Alcoholism and Substance Abuse Services.
  401. Rural Health in New York State., New York State Rural Health Council. p. 2-13.
  402. Breslin, D., A Realistic Look At Evaluation Programming For High-Risk Youth. 1993, New York State Office of Alcoholism Prevention and Intervention.
  403. Schiff, M., A Rum Tale. Adolescent Counselor, 1990: p. 45-46.
  404. Irwin, M. and F. DuFour, Regional resource Center on Seriously Emotionally Disturbed Children and Youth. 1992, Central New York Regional Office of Mental Health SUNY Health Science Center Department of Psychiatry: Syracuse, NY.
  405. Baskin, D., H. Bluestone, and M. Nelson, Mental illness in minority women. Journal of Clinical Psychology, 1981. 37(3): p. 491-8.
  406. Lander, R., Clues to Possible Substance Abuse. Adolescent Counselor, 1992: p. 13.
  407. Maine Rural Health Research Center Current Projects.
  408. Snustad, D.G., et al., Mental Health Outreach to Rural Elderly: Service Delivery to a Forgotten Risk Group, in The Forgotten Aged: Ethnic, Psychiatric, and Societal Minorities, T.L. Brink, Editor. 1993, The Hawthorn Press, Inc. p. 95-111.
  409. Beck, A.T., Suicide Intent Scale. 1978.
  410. Badger, L.W., et al., The case for integration of social work psychosocial services into rural primary care practice. Health & Social Work, 1997. 22(1): p. 20-9.
  411. Conger, R.D., The special nature of rural America. NIDA Research Monograph, 1997. 168: p. 37-52.
  412. Smith, K., R. Conroy, and B.D. Ehler, Lethality of Suicide Attempt Scale.
  413. Schaefer, Ethnic and Racial Variations in Alcohol use and Abuse., National Clearinghouse for Alcohol Information: Rockville.
  414. Rubin, M.R., Formication, Substance Dependence, and AIDS: The Complexity of Today's Psychiatric Patient, in Carrier Foundation Letter. 1990.
  415. Cocaine Addicts: More Prone to Haloperidol-Induced Dystonia? New Medical Science, 1987: p. 6.
  416. Smith, G.L. and K. Kelley, Traveling the Information Superhighway: Mental Health Delivery on the Road to Rural America.
  417. Biglan, A., et al., A drug abuse prevention strategy for rural America. NIDA Research Monograph, 1997. 168: p. 364-97.
  418. generic model of locus of care based on everity of mental illness and alcohol and drug dependencies.
  419. Carey, K.B. and M.P. Carey, Enhancing the treatment attendance of mentally ill chemical abusers. Journal of Behavior Therapy & Experimental Psychiatry, 1990. 21(3): p. 205-9.
  420. OMH/OASAS Forum on Rural Services for Persons in Dual Recovery. 1998.
  421. Fact Sheet on Drugs Most Frequently Abused., The Dede Wallace Nashville Drug Treatment Center: Nashville, TN.
  422. Sciacca, K., Sciacca comprehensive Service Development for Mental Illness, Drug Addiction & Alcoholism. 1997.
  423. Carroll, J.F.X. and J.J. MnGinley, MENTAL HEALTH SCREENING FORM. 2000, Project Return Foundation.
  424. Sciacca, K., Curriculum for Direct Care Providers: Mental Illness, Drug Addiction and Alcoholism, MIDAA: Training, Cross-Training, and Program Development. 1997, Managed Care Initiative panel.
  425. Dual Diagnosis Competency Examination Self-Study Workbook. 1999.
  426. Congress Acknowledges Unique Concerns for Rural America in Health Care Reform. 1994.
  427. Generic Model of Locus of Care Based on Severity of Mental Illness and Alcohol and Drug Dependencies. 1998, NYS Office of Alcoholism and Substance Abuse Services.
  428. Nayowith, G. and E. Frankford, Private Troubles, Public Challenges: Serving Emotionally Disturbed Children and Their Families. 1992.
  429. Talbott, J.A., Chronic Mentally Ill Young Adults (18-40) with Substance Abuse Problems: A Review of Relevant Literature and Creation of a Research Agenda. 1986, Alcohol, Drug Abuse and Mental Health Administration U.S. Department of Health and Human Services and Department of Health and Mental Hygiene State of Maryland.
  430. Closing the Gaps: Creating an Integrated Service System for People with Co-Occuring Psychiatric and Addictive Disorders. The coalition of voluntary mental health agencies, inc., 2000.
  431. Fine, J., Models for Evaluation and Management of Concurrent Psychiatric and Addictive Disturbances, in Parenting for Prevention, How to Raise a Child to Say No to Alcohol/Drugs, For Parents, Teachers, and Other Concerned Adults, D. Wilmes, Editor. 1988, Johnson Institute Books: Minneapolis.
  432. Providing Coherent Treatment to Those with Co-occuring Addictive and Mental Disorders Requires New Vision. Mental Health Issues Today, 1997. 1(2).
  433. Principles for the Care and Treatment of Persons with Co-Occuring Psychiatric and Substance Abuse. 2000.
  434. AACP Guidelines for Psychiatric Leadership in Organized Delivery Systems for Treatment of Psychiatric and Substance Disorders.
  435. LOCUS-Level of Care Utilization System Psychiatric and Addictive Services. 1997.
  436. Bricker, M.G., Support together for Emotional/Mental Serenity & Sobriety: A "Cookbook" Approach to Group Development & Implementation for Dual Recovery Clients. 1992, United Behavioral Systems: West Bend.
  437. Carey, K.B., Coexistence of Mental Illness and Substance Abuse: A Bibliography of Recent Theory, Research, and Practice. 1989, Richard H. Hutchings Psychiatric Center: Syracuse, NY.
  438. Carey, M.P., K.B. Carey, and B.A. Meisler, Psychiatric Symptoms in Mentally Ill Chemical Abusers.
  439. Carey, K.B. and M.P. Carey, Social Problem-Solving in Dual Diagnosis Patients. 1998, Hutchings Psychiatric Center and Syracuse University: Syracuse, NY.
  440. Carey, M.P., K.B. Carey, and B.A. Meisler, Training Mentally Ill Chemical Abusers in Social Problem Solving., Syracuse University and Hutchings Psychiatric Center: Syracuse.
  441. Hill, A., Treatment and Prevention of Alcoholism in the Native American Family, in Alcoholism and Substance Abuse in Special Populations.
  442. Alcocer, A.M., Alcohol Use and Abuse Among the Hispanic American Population.
  443. Nathan, K.I., W.H. Bresnick, and S.L. Batki, Cocaine Abue and Dependence: Approaches to Management. 1998: p. 43-59.
  444. Regulations Governing MICA Providers. 1992.
  445. Comprehensive Survey: Training Needs For Children's Mental Health.
  446. Alexander, M.J. and G. Haugland, Integrating Services for Co-Occuring Disorders. 2000, The New York State Conference of Local Mental Hygiene Directors: Orangeburg, NY.
  447. Mental Health Family Support Services Respite Programs.
  448. Farberow, N.L., Summary, in The Psychotherapeutic Cry for Help, E. Schneidman, Editor. 1961, McGraw Hill. p. 290-305.
  449. Quick Guide for Cross-Cultural Counseling.
  450. Increase New York State's Committment to Alcoholism and Substance Abuse Prevention and Treatment., New York State Association of Alcoholism and Substance Abuse Providers, Inc.: Albany, NY.
  451. Maximizing our Resources: Coordinating Community Services to Reduce Social Problems Caused by Alcoholism and Substance Abuse., New York State Association of Alcoholism and Substance Abuse Providers, Inc.: Albany, NY.
  452. alcohol/drugs/psychotropic medication.
  453. Travers, W.L., Protocol for MICA Assessment.
  454. Tommasello, T., Cocaine Dependence And Treatment: The Pharmacological Aspects. PharmAlert, 1984. 15(1).
  455. TRC CODEBOOK.
  456. Carroll, J.F.X. and J.J. McGinley, Guidelines for using the mental health screening form III. 2000.
  457. Listings of The Technical Assistance Publications (TAPS) in series and The Treatment Improvement Protocol (TIP) Series from the Center for Substance Abuse Treatment., National Clearinghouse Fo Alcohol and Dug Information.
  458. Substance Abuse and Mental Health Services Linkages with Primary Care: Analysis of State Surveys and Case Studies. 1998, National Associatioon of State Mental Health Program Directors Research Institute and the National Association of State Alcohol and Drug Abuse Directors.
  459. hostetler, J.R., Alcohol and Drug Abuse Teaching Methadology Guide for Medical Faculty. 1982, Rockville, Maryland. 42.
  460. Rahdert, E., Curriculum for Co-Morbidity and Youth: Psychiatric Disorders, Substance Use and Abuse., Office for Substance Abuse Prevention.


Last Modified: Feb 18, 2005
Contact Sharon Givens with questions about the content of this page.
Privacy Policy | Patient Privacy Notice PDF document text | Emergency Information
All contents copyright © 1988-2008, SUNY Upstate Medical University

v 1.0